Trials / Terminated
TerminatedNCT02702518
rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
A Phase I/II Randomized Placebo-Controlled, Double-Blind, Single-Center, Tolerability and Preliminary Efficacy Clinical Trial of Recombinant Human Deoxyribonuclease (rhDNase) Eye Drops in Patients With Ocular Graft-Vs.-Host Disease
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- University of Illinois at Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the tolerability and preliminary efficacy of rhDNase I eye drops in patients with ocular Graft-vs.-Host disease (oGVHD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rhDNase I | rhDNase I, 0.1% eye drops 4 times a day for 8 weeks |
| DRUG | Vehicle | Drug vehicle 4 times a day for 8 weeks |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2020-04-08
- Completion
- 2020-04-08
- First posted
- 2016-03-08
- Last updated
- 2021-09-05
- Results posted
- 2021-08-10
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02702518. Inclusion in this directory is not an endorsement.